IDBS, a world leader in the management of drug discovery data, today announced the latest implementation of their flagship product, ActivityBase. J.Uriach (Barcelona, Spain) plan to improve their current developmental focus on inflammatory diseases through the deployment of the ActivityBase solution. The company’s 165-year heritage has resulted in many successful products, including the drug Triflusal (DisgrenTM), currently one of the most prescribed antithrombotic agents in Spain.
